TTX 334Ab Oncology

Background

The discovery of TTX-334Ab Oncolgy emerged serendipitously from our original provocative finding that a cell surface marker, previously only thought to be expressed on immune cells, was expressed in epithelial ovarian cancer (EOC) cells and tissues.

Rigorous in vitro and in vivo testing of endometrial cells and numerous ovarian as well as other cancer cell lines with various sources of the antibody reproducibly demonstrated its remarkable cell killing effect with abnormally growing cells. More importantly, the antibody did not kill normal ovarian surface epithelial cells, nor did it kill macrophages, which are known to express excessive amounts of the myeloid antigen.

 

 

Mode of Action TTX 334Ab Oncology

Mode of Action

The expression of novel antigen and MPO in EOC cell and tissues suggests a paracrine/autocrine mechanism of survival. Interruption of this binding via targeting novel antigen with TTX334Ab resulted in significant anti-tumorigenic effects in vivo and in vitro. We report a unique target for immunotherapy in ovarian cancer, and potentially other cancers, which is based on a novel survival mechanism.

 

 

 

TTX 334Ab Key Takeaways

Potent and reproducible anti-tumor effect of TTX-334 has been demonstrated

TTX-334 does not appear to harm normal cells

Recognizes a novel antigen

Anti-tumor effect observed  in vitro in various cancer cell lines including colon (HTB-37), endometrial (CRL-1671), lung (CCL-257), prostate (CRL-1740), bladder (HTB-4), and hepatocelluar (HB-8065) cancers.

Anti-tumor, cell killing effect demonstrated in vitro in cisplatin sensitive and resistant ovarian tumor cell lines, endometriosis and fibrosis

Efficacy demonstrated in vivo in mouse xenograft model of human ovarian cancer (cell line SKOV-3)

Mechanism of action involves induction of apoptosis in cancer cells

Not species or source specific

MeEt Us

View our upcoming events

View All Events